13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • SEAGEN SGNLVA SOLIDS

    Acronym: 

    SEAGEN SGNLVA

    ACTRN/NCT /ethics: 

    NCT04032704

    Scientific title: 

    Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

    Summary of trial and patient characteristics

    Cancer Type All cancers, Lung & mesothelioma, Head and Neck, Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase II Tumour Stream Solid tumours
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2019-10-09
    Molecular Target Anticipated End Date 2021-04-30
    Cancer Type All cancers, Lung & mesothelioma, Head and Neck, Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid tumours
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2019-10-09
    Anticipated End Date 2021-04-30

    Trial Summary

    This trial will study Ladiratuzumab Vedotin (LV) to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur.

    Lay Summary

    Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

    Sponsor / Cooperative group

    Seattle Genetics, Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Dr Chris Karapetis Not Yet Recruiting